Cargando…
Treatment and vaccines for severe acute respiratory syndrome
The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002–2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106466/ https://www.ncbi.nlm.nih.gov/pubmed/15766649 http://dx.doi.org/10.1016/S1473-3099(05)01307-1 |
_version_ | 1783512612214931456 |
---|---|
author | Groneberg, David A Poutanen, Susan M Low, Donald E Lode, Hartmut Welte, Tobias Zabel, Peter |
author_facet | Groneberg, David A Poutanen, Susan M Low, Donald E Lode, Hartmut Welte, Tobias Zabel, Peter |
author_sort | Groneberg, David A |
collection | PubMed |
description | The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002–2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur. |
format | Online Article Text |
id | pubmed-7106466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71064662020-03-31 Treatment and vaccines for severe acute respiratory syndrome Groneberg, David A Poutanen, Susan M Low, Donald E Lode, Hartmut Welte, Tobias Zabel, Peter Lancet Infect Dis Article The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002–2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur. Elsevier Ltd. 2005-03 2005-03-10 /pmc/articles/PMC7106466/ /pubmed/15766649 http://dx.doi.org/10.1016/S1473-3099(05)01307-1 Text en Copyright © 2005 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Groneberg, David A Poutanen, Susan M Low, Donald E Lode, Hartmut Welte, Tobias Zabel, Peter Treatment and vaccines for severe acute respiratory syndrome |
title | Treatment and vaccines for severe acute respiratory syndrome |
title_full | Treatment and vaccines for severe acute respiratory syndrome |
title_fullStr | Treatment and vaccines for severe acute respiratory syndrome |
title_full_unstemmed | Treatment and vaccines for severe acute respiratory syndrome |
title_short | Treatment and vaccines for severe acute respiratory syndrome |
title_sort | treatment and vaccines for severe acute respiratory syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106466/ https://www.ncbi.nlm.nih.gov/pubmed/15766649 http://dx.doi.org/10.1016/S1473-3099(05)01307-1 |
work_keys_str_mv | AT gronebergdavida treatmentandvaccinesforsevereacuterespiratorysyndrome AT poutanensusanm treatmentandvaccinesforsevereacuterespiratorysyndrome AT lowdonalde treatmentandvaccinesforsevereacuterespiratorysyndrome AT lodehartmut treatmentandvaccinesforsevereacuterespiratorysyndrome AT weltetobias treatmentandvaccinesforsevereacuterespiratorysyndrome AT zabelpeter treatmentandvaccinesforsevereacuterespiratorysyndrome |